Brain Metastasis in Breast Cancer Patients

Sponsor
GlaxoSmithKline
Study ID
NCT01077648
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
FEMALE
Age
30 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Trastuzumab or Lapatinib — DRUG
    Anti-erbB2 therapy for breast cancer treatment will be analyzed as a class level variable; individual drugs including trastuzumab and lapatinib will also be explored as exposures if sufficient numbers of patients exist.

Study Details

The purpose of this epidemiologic study is to establish a population-based cohort of women with advanced stage breast cancer which can be used to quantify the frequency and timing of brain metastases, and other distant metastases, in this patient population.

Key Dates

Start date
Feb 28, 2010
Status verified
May 2014
Primary completion
Aug 31, 2013
Completion
Aug 31, 2013

Study Design

Enrollment
1 participants (actual)

Arms

  • Arm: Women diagnosed with advanced breast cancer
    Women diagnosed with advanced breast cancer during January 1, 1995-December 31, 2007 and treated as part of the Henry Ford Health System

Primary Outcome Measure

Proportion of advanced stage breast cancer patients that develop brain metastases, overall and stratified by anti-HER2 therapy (for HER2+ patients only). [ Time Frame: Time from breast cancer diagnosis until death or end of study periods (September 1, 2009) ]

Related Studies